Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
sell

SELLAS Life Sciences Group Inc sell nvestor

SELLAS Life Sciences Group Inc
Start price
€3.71
02.04.22 / 50%
Target price
€1.00
02.04.23
Performance (%)
-16.30%
End price
€3.11
16.04.22
Summary
This prediction ended on 16.04.22 with a price of €3.11. The prediction for SELLAS Life Sciences Group Inc closed with a convincing performance of -16.30%. nvestor has 50% into this prediction

SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.

Performance without dividends (%)
Name 1w 1m 1y
SELLAS Life Sciences Group Inc -10.147% -10.147% -7.143%
iShares Core DAX® -0.922% -1.993% 13.399%
iShares Nasdaq 100 0.371% -0.868% 41.541%
iShares Nikkei 225® 2.224% -5.187% 20.497%
iShares S&P 500 -0.026% -0.918% 30.410%

Comments by nvestor for this prediction

In the thread SELLAS Life Sciences Group Inc diskutieren
Prediction Sell
Perf. (%) -16.30%
Target price 1.000
Change
Ends at

Sell mit Kursziel 1,0

nvestor 
0
Report Share
02.04.22
In the thread Trading SELLAS Life Sciences Group Inc
Prediction Sell
Perf. (%) -16.30%
Target price 1.000
Change
Ends at 02.04.23

Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.

nvestor 
0
Report Share
16.04.22